Study to Treat Uveitis Associated Macular Edema
The purpose of this study is to determine whether denufosol tetrasodium (INS37217) Intravitreal Injection is well tolerated and has the potential to treat uveitis associated macular edema.
Cystoid Macular Edema
Drug: denufosol tetrasodium (INS37217) Intravitreal Injection
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose Ranging Pilot Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Uveitis Associated Macular Edema|
- Evaluate the safety and tolerability of denufosol in subjects presenting with uveitis associated macular edema.
- Assess the utility of denufosol in treating uveitis associated macular edema.
- Pilot study - not specified
|Study Start Date:||May 2005|
|Primary Completion Date:||December 2006 (Final data collection date for primary outcome measure)|
Denufosol tetrasodium (INS37217) Intravitreal Injection may provide clinical benefit in treatment of uveitis associated macular edema (UME) by reducing retinal thickness as measured by OCT and possibly enabling recovery of vision loss associated with UME. Denufosol tetrasodium may also reverse the fluid accumulation of UME.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00114062
|Study Director:||Amy Schaberg, BSN|